Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers

References

• American Cancer Society. Cancer facts & figures 2010. Atlanta, GA: American Cancer Society, 2010
   Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
   PubMed Web of Science ®Google Scholar
• Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-9
   PubMed Web of Science ®Google Scholar
• Saad F, Eastham J. Maintaining bone health in prostate cancer throughout the disease continuum. Semin Oncol 2010;37(1 Suppl):S30-7
   Google Scholar
• Saad F, Eastham JA. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 2010;37(1 Suppl):S38-44
   Google Scholar
• Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34:S17-23
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
   PubMed Web of Science ®Google Scholar
• Zekri J, Ahmed N, Coleman RE, et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379-82
   PubMed Web of Science ®Google Scholar
• Zaghloul MS, Boutrus R, El-Hossieny H, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010;15:382-9
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Castel LD, Li Y, et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-75
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
   PubMed Web of Science ®Google Scholar
• Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008;26:2544-9
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21
   PubMed Web of Science ®Google Scholar
• Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390-6
   PubMed Web of Science ®Google Scholar
• Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7
   PubMedGoogle Scholar
• Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006;1:571-6
   PubMed Web of Science ®Google Scholar
• Logman J, Botteman M, Kaura S. Cost-effectiveness assessment of zoledronic acid (ZOL) relative to placebo (PBO) in the treatment of lung cancer patients with skeletal metastases in five European countries. Presented at ISPOR 12th Annual European Congress; Paris, France; October 24–27, 2009
   Google Scholar
• Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51
   PubMed Web of Science ®Google Scholar
• Xie J, Namjoshi M, Wu EQ, et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011;17:621-34
   PubMed Web of Science ®Google Scholar
• Berry S, Waldron T, Winquist EW, et al. The use of bisphosphonates in men with hormone-refractory prostate cancer. Practice Guideline Report #3-14. Cancer Care Ontario. Published January 10, 2005. https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc3-14f.pdf. Accessed December 6, 2011
   Google Scholar
• Saad F, Chen YM, Gleason DM, et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007;5:390-6
   PubMed Web of Science ®Google Scholar
• Mulders PFA, Miller K, Tchekmedyian NS, et al. Long-term reduction in risk of skeletal complications with zoledronic acid in patients with advanced renal cell carcinoma or bladder cancer. Presented at 22nd Annual EAU Congress; Berlin, Germany; March 21, 2007
   Google Scholar
• Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 2002;40:675-85
   PubMed Web of Science ®Google Scholar
• Kaura S, Henk H. Retrospective database analysis of zoledronic acid treatment patterns in patients with renal cell carcinoma or bladder cancer and bone metastases. Presented at 25th Annual EAU Congress; Barcelona, Spain; April 16–20, 2010
   Google Scholar
• Botteman MF, Kaura S. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: comparison between France, Germany, and the United Kingdom. Presented at 45th Annual Meeting of the American Society of Clinical Oncology; Orlando, FL; May 29–June 2, 2009
   Google Scholar
• Cereceda LE, Flechon A, Droz JP. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer 2003;2:34-40
   PubMedGoogle Scholar
• Kinnane N. Burden of bone disease. Eur J Oncol Nurs 2007;11:S28-31
   Web of Science ®Google Scholar
• Abrahamsson PA, Ostri P, Andersen M, et al. Nordic observational study evaluating safety and analgesic consumption in patients with advanced cancer under zoledronic acid (ZOMETA®) treatment: NOSAZ—interim analysis. Presented at 23rd Annual EAU Congress; Milan, Italy; March 26–29, 2008
   Google Scholar
• Rodrigues P, Hering F, Campagnari JC. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 2004;7:350-4
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-9
   PubMed Web of Science ®Google Scholar
• Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21:2188-94
   PubMed Web of Science ®Google Scholar
• Lipton A, Seaman J, Zheng M. Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Presented at What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates—From the Laboratory to the Patient; Davos, Switzerland; March 24–26, 2004
   Google Scholar